The Obesity Shot That Could Turn Monthly Into the New Weekly
MBX Biosciences just posted Phase 1 data for an obesity shot you'd only take once a month, with almost no nausea. In a market where most patients quit their weekly GLP-1s within a year, the adherence angle alone could be worth billions.
One Injection. One Month. Done.
Imagine if instead of a weekly alarm reminding you to jab yourself with an obesity drug, you only had to think about it once a month. Like paying rent, but for your metabolism.
That's what MBX Biosciences is betting on. The small Indiana-based biotech just dropped early Phase 1 data for MBX-4291, a once-monthly injectable that targets the same receptors as Eli Lilly's blockbuster tirzepatide (Zepbound). The results: 7% average weight loss in eight weeks, with almost zero gut side effects. In a world where nausea is practically a rite of passage for GLP-1 users, that last part matters enormously.
The Adherence Problem Nobody Wants to Talk About
Weekly GLP-1 shots like Wegovy and Zepbound work. The clinical trials prove it. But here's the uncomfortable truth: fewer than a third of patients on obesity injectables are still taking them after one year in the real world.
The reasons are predictable. Side effects (hello, nausea). Cost ($12,000+ annually). And plain old human nature; even weekly dosing is enough friction for people to fall off. One large study found that 65% of people without diabetes discontinued their GLP-1 within 12 months.
The pattern is clear: less frequent dosing equals better sticking with it. And if weekly beats daily, monthly should beat weekly. That's the logic driving MBX-4291.
What the Data Actually Show
Let's be clear about what we know and don't know. This is Phase 1 data, still blinded, from a small group of patients. It's the biotech equivalent of a first date that went well; promising, but way too early to pick out china patterns.
The study enrolled adults with a BMI of 30 or above across multiple dose cohorts. In the first multiple-ascending-dose group (eight people total, six on drug and two on placebo), participants lost a mean of 7% body weight over eight weeks. The range was wide: 0% to 16%. Because the trial is blinded, we can't separate drug responses from placebo yet.
But the tolerability story is where things get interesting. Across all the data reported so far, there was (diarrhea). No nausea. No vomiting. For context, nausea is one of the most common side effects reported in GLP-1 receptor agonist trials. If MBX-4291's clean GI profile holds up in larger studies, it would be a genuine differentiator.
More from this issue
View full issue →
Clinical & Regulatory4 min read
Pfizer Just Crashed the Hardest Party in Hemophilia
Pfizer just won EU approval to treat the hardest cases in hemophilia: patients whose immune systems attack their own medication. The Phase 3 data showed a 93% drop in bleeding, and the competitive implications are fascinating.
Funding & Financings
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
